Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib +/- Bevacizumab in Advanced Ovarian Cancer
NCT05009082Phase 3Recruiting
- Sponsor
- AGO Study Group
- Start
- Sep 2022
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of niraparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by AGO Study Group. Primary endpoint: Progression Free Survival up to 3 years. Started Sep 2022; status: recruiting.
02
Drugs
niraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05009082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05009082.